Metsera (MTSR) Competitors $29.38 -5.20 (-15.04%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, BBIO, ELAN, and VRNAShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Revolution Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Ascendis Pharma A/S (NASDAQ:ASND) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings. Does the media prefer ASND or MTSR? In the previous week, Metsera had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 26 mentions for Metsera and 16 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.92 beat Metsera's score of 0.77 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metsera 8 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ASND or MTSR more profitable? Metsera has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-104.54% N/A -39.23% Metsera N/A N/A N/A Which has preferable earnings & valuation, ASND or MTSR? Metsera has lower revenue, but higher earnings than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$368.70M28.30-$409.12M-$6.28-27.20MetseraN/AN/AN/AN/AN/A Does the MarketBeat Community believe in ASND or MTSR? Ascendis Pharma A/S received 452 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 67.30% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformAscendis Pharma A/SOutperform Votes45767.30% Underperform Votes22232.70% MetseraOutperform Votes5100.00% Underperform VotesNo Votes Do analysts prefer ASND or MTSR? Ascendis Pharma A/S currently has a consensus target price of $220.67, suggesting a potential upside of 29.20%. Metsera has a consensus target price of $50.00, suggesting a potential upside of 70.18%. Given Metsera's higher possible upside, analysts plainly believe Metsera is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMetsera beats Ascendis Pharma A/S on 5 of the 9 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09B$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6419.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / BookN/A6.536.974.60Net IncomeN/A$143.25M$3.23B$248.06M7 Day Performance6.88%0.21%-0.98%-1.03%1 Month Performance12.57%10.92%7.70%3.50%1 Year PerformanceN/A2.44%31.32%12.68% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$29.38-15.0%$50.00+70.2%N/A$3.09BN/A0.0081News CoverageAnalyst ForecastAnalyst RevisionGap DownASNDAscendis Pharma A/S3.389 of 5 stars$173.06-2.5%$216.73+25.2%+30.2%$10.83B$368.70M-24.37640Analyst ForecastAnalyst RevisionMRNAModerna4.4413 of 5 stars$27.46+5.1%$53.58+95.1%-81.5%$10.62B$3.14B-2.963,900Trending NewsGap DownVTRSViatris2.5133 of 5 stars$8.71+3.0%$10.40+19.4%-14.5%$10.22B$14.33B-11.7737,000QGENQiagen3.336 of 5 stars$45.48-0.2%$48.42+6.5%+10.2%$10.11B$2.00B126.646,030BPMCBlueprint Medicines1.1558 of 5 stars$127.850.0%$129.35+1.2%+20.8%$8.26B$562.12M-118.38640High Trading VolumeROIVRoivant Sciences2.3485 of 5 stars$11.23+0.3%$17.50+55.8%+5.9%$8.01B$29.05M-74.86860RVMDRevolution Medicines4.4239 of 5 stars$41.09+2.2%$67.08+63.3%+2.8%$7.65B$742K-11.45250Positive NewsBBIOBridgeBio Pharma4.5435 of 5 stars$38.62+0.7%$57.09+47.8%+38.2%$7.33B$127.42M-13.55400Insider TradeAnalyst RevisionELANElanco Animal Health1.0374 of 5 stars$13.95+3.8%$15.17+8.8%-20.6%$6.93B$4.43B34.869,800Gap DownVRNAVerona Pharma2.1246 of 5 stars$84.34-1.4%$82.13-2.6%+527.1%$6.84B$118.54M-43.9330Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives BPMC Alternatives ROIV Alternatives RVMD Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
